Appeal No. 95-4914
Application No. 08/036,116
about 0.5 to 30% of a first component of an oily liquid, about
0.1 to 10% of a second component of an emulsifier and about
0.05 to 5% of a surfactant, said droplets having a mean
droplet size in the range of 0.05 to 0.5 µm, wherein said
composition provides an enhanced topical and/or transdermal
systemic effect compared to the same compositions which have
larger size droplets.
3. The composition of claim 1 wherein the first component
comprises a medium chain triglyceride oil comprises a chain
length of 8 to 12 carbons, a vegetable oil, a mineral oil, an
oil of animal source, a synthetic derivative thereof, or
mixtures thereof.
5. The composition of claim 1 wherein the emulsifier is a
phospholipid compound or a mixture of phospholipids.
6. The composition of claim 5 wherein the phospholipid is
lecithin, phosphatidylcholine, phosphatidylethanolamine or
mixtures thereof.
35. A composition for enhanced topical and/or transdermal
delivery of pharmaceuticals comprising submicron droplets
having a mean droplet size of 0.05 to 0.3 microns dispersed in
an aqueous medium containing one or more pharmaceutically-
acceptable surfactants, wherein said droplets are comprised of
an effective amount of a water-insoluble drug mixed with one
or more medium chain triglyceride oils having a chain length
of eight to twelve carbons.
The references of record relied upon by the examiner are:
de Vringer EPA 0506197 Sep. 30, 1992
Snyder EPA 0014509 Aug. 20, 1980
The following rejections are before us:
1) claims 1-16, 23-27, 29, and 30 under 35 U.S.C. § 103
as unpatentable over de Vringer;
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007